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ABSTRACT

Apoptosis, a form of programmed cell death, is critical to homoeostasis, normal
development, and physiology. Dysregulation of apoptosis can lead to the accumulation
of unwanted cells, such as occurs in cancer, and the removal of needed cells or
disorders of normal tissues, such as heart, neurodegenerative, and autoimmune
diseases. Noninvasive detection of apoptosis may play an important role in the
evaluation of disease states and response to therapeutic intervention for a variety of
diseases. It is desirable to have an imaging method to accurately detect and monitor
this process in patients. In this study, we developed annexin A5-conjugated polymeric
micellar nanoparticles dual-labeled with a near-infrared fluorescence fluorophores (Cy7)
and a radioisotope (111In), named as

111

In-labeled annexin A5-CCPM. In vitro studies

demonstrated that annexin A5-CCPM could strongly and specifically bind to apoptotic
cells. In vivo studies showed that apoptotic tissues could be clearly visualized by both
single photon emission computed tomography (SPECT) and fluorescence molecular
tomography (FMT) after intravenous injection of

111

In-labeled Annexin A5-CCPM in 6

different apoptosis models. In contrast, there was little signal in respective healthy
tissues. All the biodistribution data confirmed imaging results. Moreover, histological
analysis revealed that radioactivity count correlated with fluorescence signal from the
nanoparticles, and both signals co-localized with the region of apoptosis. In sum,

111

In-

labeled annexin A5-CCPM allowed visualization of apoptosis by both nuclear and
optical imaging techniques. The complementary information acquired with multiple
imaging techniques should be advantageous in improving diagnostics and management
of patients.
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INTRODUCTION

1. Apoptosis
1.1 Mechanism of Apoptosis
Apoptosis, a form of programmed cell death, is defined as a regulated
energy-dependent process, characterized by specific morphological and
biochemical features in which caspases play a central role. Apoptosis is
considered a critical component of multiple biological processes, which include
normal cell turnover, embryonic development, hormone-dependent atrophy,
proper development and functioning of the immune system, and chemicalinduced cell death (1-9). The mechanisms of apoptosis are highly complex,
which involve a cascade of molecular events. To date, it is well known that there
are three main apoptotic pathways, including the extrinsic pathway, the intrinsic
pathway, and perforin/granzyme pathway (Fig. 1). These three pathways
converge on the same terminal and execution pathway, which is initiated by the
cleavage of caspase-3 and leads to DNA fragmentation, proteins cross-linking,
proteins degradation, formation of apoptotic bodies, expression of ligands for
phagocytosis and finally uptake by phagocytic cells (1-9).
In general, a variety of injurious stimuli such as radiation, heat, hypoxia
and drugs can induce apoptosis. In this study, to mimic massive apoptosis that
occurs in some tissues, we use anticancer drugs (e.g.

cyclophosphamide,

etoposide, poly(L-glutamic acid)-paclitaxel and cetuximab) to induce tumor
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Figure 1. Schematic representation of apoptotic events. The three main
pathways of apoptosis are extrinsic and intrinsic as well as a perforin/granzyme
pathway. Each requires specific triggering signals to begin an energy dependent
cascade of molecular events. Each pathway activates its own initiator caspase
(8, 9, 10) which in turn will activate the executioner caspase-3. However,
granzyme A works in a caspase-independent fashion. The execution pathway
results in characteristic cytomorphological features including cell shrinkage,
chromatin condensation, formation of cytoplasmic blebs and apoptotic bodies
and finally phagocytosis of the apoptotic bodies by adjacent parenchymal cells,
neoplastic cells or macrophages. (Reprinted with permission of (9))

apoptosis (10-13), anti-Fas antibody to induce hepatic apoptosis (14), and
turpentine to induce muscle inflammation (15). Cyclophosphamide is widely
used to treat several types of cancer, such as lymphoma, leukemia, breast
cancer, and ovarian cancer (16-18). Anti-Fas antibody, which binds to hepatic
Fas receptors, can be used to induce massive apoptosis of hepatocytes in mice
within a few hours, mimicking fulminant hepatitis (19). Turpentine can be used
as a stimulus to trigger a series of inflammation reactions after intramuscular

~2~

injection, such as migration of granulocytes to the injured tissues, and clearance
of apoptotic granulocytes through PS-specific recognition by monocytes (15).

1.2 Importance of Imaging Apoptosis
Dysregulation of apoptosis can lead to a number of diseases. Too little
apoptosis can result in accumulation of unwanted cells, such as occurs in
cancer, rheumatoid arthritis, systemic lupus erythematosus (SLE), and
autoimmune lymphoproliferative syndrome (ALPS). In contrast, too much
apoptosis can lead to the removal of needed cells or disorders of normal tissues,
such as acute myocardial infarction (AMI), chronic heart failure, allograft
rejection,

stroke,

inflammation,

autoimmune

diseases

(AIDS),

and

neurodegenerative diseases (e.g. Parkinson’s disease, Alzheimer’s disease,
Huntington’s

disease,

and

Amyotrophic

Lateral

Sclerosis)

(1,

20-28).

Additionally, the detrimental or beneficial effect of many drugs is attributed to
their action on the apoptotic process (20, 29-31). For example, chemotherapy
and radiotherapy are widely used in clinic to induce tumor apoptosis. Since
apoptosis is involved in a number of diseases and therapeutic procedures, it is
necessary to in vivo monitor the rate and extent at which apoptosis occurs
(Table 1). The purpose of this project is to develop a non-invasive imaging
tracer for detection of apoptosis, which may provide relevant information on
disease activity and therapeutic efficacy.

~3~

Table 1. Medical field for application of apoptosis imaging. Abbreviations: AMI,
Acute myocardial infarction; ARVD, arrhythmogenic right ventricle dysplasia;
CAD, coronary artery disease; CHF, congestive heart failure; MODS, multiple
organ dysfunction syndrome; SLE, systemic lupus erythematosus. (Reprinted
with permission of (20))
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1.3 Assays for Apoptosis
During apoptosis, cells exhibit several biochemical modifications, such as
protein

cleavage,

protein

cross-linking,

morphological

change,

DNA

fragmentation, and expression of cell surface markers, which together lead to
the distinctive structural pathology described previously (3, 9). Thus, a variety of
apoptosis assays are devised to detect and count apoptotic cells. Based on
methodology, current apoptosis assays can be classified into six major groups
and a subset of specific assays in each group is listed in Table 2. (Reprinted
with the permission of (9))

Methodology

Techniques

Cytomorphological alterations

Hematoxylin and eosin staining (H&E);
Transmission electron microscopy (TEM).

DNA fragmentation

DNA laddering;
Terminal dUTP nick end labeling (TUNEL).

Detection of caspases, cleaved substrates,

Immunostaining (anti-caspase antibody);

regulators and inhibitors

PCR microassay.

Detection of apoptosis in whole mounts

Staining (acridine orange, Nile blue sulfate,
and neutral red).

Mitochondrial assays

Laser scanning confocal microscopy (LSCM).

Membrane alterations

Fluorophore/radio-labeled annexin A5
derivatives.

Table 2. Assays for detection of apoptosis.
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Although there are a variety of assays available, each assay has
advantages and disadvantages which may make it appropriate for one
application but inappropriate for another (32, 33). ① .Cytomorphological
Changes: Based on the morphological changes during apoptosis, apoptotic cells
can be detected using transmission electron microscopy (TEM), or light
microscopy incorporated with hematoxylin and eosin (H&E) staining. TEM is
used as a golden standard to confirm apoptosis, because of certain
ultrastructural morphological characteristics (9, 34), However, because the
morphological changes generally occur in the later phase of apoptosis, apoptotic
cells in the early phase will not be detected with these methods. Additionally,
these methods, particularly TEM, only allow visualizing a small region at a time.
②.DNA Fragmentation: DNA laddering technique and terminal dUTP nick endlabeling (TUNEL) can be used to assay the endonuclease cleavage products of
apoptosis (35). Owing to commercial kits from various companies, these assays
are fast and easily accessible. The disadvantage is that these methods are only
suitable for detection of apoptosis in the later phase. ③.Detection of caspases,
cleaved substrates, regulators and inhibitors: The activation of certain proteins in
apoptotic process can be detected using western blot, immunohistochemistry, or
immunoprecipitation (36, 37). For example, anti-caspase 3 antibody was used in
this study to locate apoptotic area in tumor section. This assay allows for fast
and consistent quantification of apoptotic cells. However, because these

~6~

proteins such as caspases are involved in several different cell activities and are
not specific to apoptosis, their activation doesn’t necessarily indicate occurance
of apoptosis. ④.Detection of Apoptosis in Whole Mounts: Apoptosis also can be
visualized in whole mounts using some dyes, such as acridine orange (AO),
neutral red (NR), and Nile blue sulfate (NBS) (38). This is because these
acidophilic dyes are easily concentrated in the areas of high lysosomal and
phagocytotic activity. Although this assay is fast and inexpensive, it still has
certain disadvantages. For example, AO is toxic and quenches rapidly whereas
NBS and NR are unstable and hardly penetrate thick tissues. ⑤.Mitochondrial
Assay: some mitochondrial parameters can be monitored for detection of
apoptosis, such as mitochondrial permeability transition (MPT), Ca2+ fluxes,
reactive oxygen species, depolarization of the inner mitochondrial membrane,
and mitochondrial redox status (39, 40). However, these mitochondrial events
also occur during necrosis and other cell activities. Therefore, it is necessary to
use other apoptosis assays to confirm the result. ⑥.Membranes Alterations: Cell
plasma membranes maintain an asymmetric distribution of lipid molecules in the
bilayer. Phosphatidylserine (PS), a component of cell membrane phospholipids,
localizes in the inner plasma membrane. The intracellular localization of PS is
maintained by an ATP-dependent aminophospholipid translocase that shuttles
PS from the outer to the inner leaflet in viable cells. In the early stage of
apoptosis, cellular mechanisms which maintain PS asymmetry, become
inactivated and lead to externalization of PS on the outer surface of membrane
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(Fig. 2) (41-43). The externalized PS on the outer surface of apoptotic cells is
considered a “eat-me” signal for phagocytosis, potentially allowing for detection
of apoptosis via Fluorophore/radio-labeled annexin A5 (44). The main
advantages of this assay are sensitivity (can detect a single apoptotic cell) and
ability to detect apoptosis in the early phase. In addition, this assay is fast,
inexpensive and easy-to-use. Thus, we took advantage of this methodology for
imaging apoptosis in this study. (Reprinted with the permission of (9))

Figure 2. Maintaining normal membrane polarity by translocase and floppase
activity (left). Diagram of the cell membrane with phospholipid head groups
(circular structures) and tails (interior of the lipid bilayer), with two enzyme
channels: (1) floppase pumping sphingomyelin, phosphatidylethanolamine and
phosphatidylcholine to the exterior leaflet; and (2) translocase pumping
phosphatidylserine to the inner leaflet. Expression of phosphatidylserine due to
scramblase activation (right). Diagram of a portion of the cell membrane in a cell
undergoing apoptosis. The enzyme scramblase is activated, resulting in the
active transfer of phosphatidylserine from the inner to the outer leaflet of the cell
membrane in parallel with the transfer of the other lipids to the inner leaflet.
These changes occur as the cell membrane forms a bleb, which will break off to
form an apoptotic body. (Reprinted with permission of (43))

~8~

2. Annexin A5
2.1 Introduction of Annexin Family and Annexin A5
Annexins are well-known multigene family of calcium-regulated and
phospholipid-binding proteins expressed in most eukaryotic cells. Structurally, all
annexins share a unique core domain consist of four similar repeats, each
approximately 70 amino acids long. Despite their structural similarities, annexins
have diverse biological functions in biological activities, such as apoptosis, cell
division, calcium signaling, vesicle trafficking, regulation of membrane
organization, and regulation of growth. In the past decades, 12 annexin
members common to vertebrates were observed and classified in annexin A
family (annexins A1-A11 and A13) [4]. Annexins outside vertebrates are
classified into families B (in invertebrates), C (in fungi), D (in plants), and E (in
protists) (45-50).
Annexin A5 (molecular weight 36 KDa), also known as annexin V, is an
endogenous human protein that consists of 319 amino acids (Fig. 3), which is
widely expressed in eukaryotic organisms and mainly found intracellularly on the
cytosolic side of plasma membranes (51-55). This protein is also expressed in
various cell types, such as erythrocytes, glial cells, vascular endothelium,
thrombocytes, hepatocytes, bronchi, astrocytes, lymphocytes, chondrocytes,
oligodendrocytes,

Schwann

cells,

osteoblasts,

skeletal

muscles,

and

cardiomyocytes (56-62). In human, there is very low concentration (1–6 ng/ml) of
annexin A5 circulating in the blood pool (20). To date, several biological
properties of annexin A5 have been reported, including regulation of

~9~

phospholipase A2 (63, 64), Ca2+-channel activities (65, 66), inhibition of
phagocytosis of apoptotic cells by macrophages (67-69) and immune modulation
(70, 71).

Figure 3. X-ray analysis revealed the tertiary structure of annexin A5, as
depicted here. The protein consists of 319 amino acids. Molecule is arranged in
planar cyclic structure of 4 domains, which are indicated by different colors in
structure. Also shown are Ca2_ ions (green spheres). (Reprinted with
permission of (51))

Annexin

A5

is

known

to

specifically

and

strongly

bind

to

Phosphatidylserine on the surface of apoptotic cells with nanomolar affinity (Kd=
0.5 – 7 nM) (Fig. 4) (20, 52, 53). Recently, it was reported that annexin A5 not
only binds to PS but also forms a two-dimensional network on the surface that
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causes its internalization (72). With the onset of apoptosis, the number of
annexin A5-binding sites per cell can increase 100- to 1,000-fold, reaching
values of about 4 million in some cell lines (73, 74). Considering annexin A5 a
promising ligand which binds to apoptotic cells, we introduced it in our nanoscale imaging system in this study for targeting.

Figure 4. Schematic representation of the loss of membrane lipid asymmetry
during apoptosis. Vital cells maintain a strictly asymmetric lipid bilayer
composition, with PS residues (red circles) facing the cytosol. During apoptosis
these PS molecules become exposed at the outer membrane leaflet Haptenlabeled annexin V can bind with high affinity to the exposed PS in the presence
of millimolar Ca2+-concentration. (Reprinted with permission of (52))

~ 11 ~

2.2 Annexin A5 Derivatives for Imaging Apoptosis
Van den Eijnde and co-workers were the first to demonstrate that annexin
A5 can detect apoptosis in vivo (75). Today, annexin A5 is the most widely used
in the visualization of apoptosis. In recent years, a variety of annexin A5
derivatives have been developed for the detection of apoptosis with different
imaging modalities, including fluorescence (76, 77), positron emission
tomography (PET) (78-81), single photon emission computed tomography
(SPECT) (14, 15, 23, 82-87), and magnetic resonance imaging (MRI) (88, 89).

Table 3. List of clinical trials (phase I/III). Abbreviations: (A)MI, (Acute)
myocardial infarction; IP, ischaemic preconditioning; MRI, magnetic resonance
imaging; NSCLC, non-small cell lung cancer. (Reprinted with permission of (20))
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Among these derivatives, the radiolabeled annexin A5 analogues are the
most advanced in human clinical trials (Table 3) (14, 15, 23, 82-87). In the past
decades, a number of studies were conducted to investigate annexin A5
derivatives labeled with different radioisotopes (e.g.
18

F,

of

111

In,

11

C,

64

Cu,

67

Ga and

99m

99m

Tc,

94m

Tc,

123

I,

124

I,

125

I,

68

Ga) (20, 90). Due to the substantial advantages

Tc over many other radionuclides,

99m

Tc-labeled annexin A5 is the most

extensively investigated and broadly used. The radioisotope

99m

Tc is

inexpensive, easily available, and has short half-life (~6 h) and optimal imaging
properties for SPECT. Various radiochemical techniques of 99mTc-labeling were
used, such as indirect labeling through chelators and co-ligands (e.g. N2S2,
HYNIC, EC, MAG3, BTAP, EDDA, SDH, iminothiolane, tricarbonyl) or direct
labeling with annexin A5 mutants (20). The improvement of radiochemistry leads
to better radiochemical purity, efficiency, stability, and in vivo imaging properties
(e.g. biodistribution and pharmacokinetics) (91-98). Currently, the radiolabeling
procedure was further improved into a kit formulation which only requires 15 min
for reaction. Moreover, the specific activity is very high and reaches 198–265
GBq/μmol, making

99m

Tc-labeled annexin A5 much more useful for in vivo

imaging applications (20).
Annexin A5 also can be conjugated with fluorochromes for optical
imaging of apoptosis. Koopman et al. first reported a flow cytometric method for
detection of PS expression on apoptotic B cells by fluorochrome-labeled annexin
A5 (99). To date, this kind of fluorochrome-labeled annexin A5 incorporated with
fluorescence-activated cell sorting (FACS) and flow cytometry (100, 101) are
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now routinely used to identify apoptotic cells. It was also reported that annexin
A5 labeled with near-infrared fluorescence dye (Cy5.5) could be applied for
imaging tumor apoptosis in vivo (102). This optical approach could overcome
some limitations of radioligands, such as radiation exposure, high cost, and a
limited time window for consecutive monitoring apoptosis due to a short half-life.
Moreover, optical imaging technique allows monitoring ongoing apoptosis in real
time. However, owing to limited tissue penetration depth of light, optical imaging
is mostly used for in vitro detection of apoptosis, or combined with other imaging
modalities to provide complimentary information.
In effort to develop a non-invasive imaging modality for in vivo detection
of apoptosis, annexin A5 recently was conjugated with some MRI contrast
agents, such as super paramagnetic iron oxide nanoparticles (SPIO) and crosslinked iron oxide nanoparticles (CLIO) (88, 103). Both contrast agents showed a
considerable potential for successful detection of apoptosis by MRI.
In this project, with respect to en-vogue concept of multimodal imaging,
annexin A5 was conjugated to nanoparticles dual-labeled with radioisotopes and
fluorochromes. This design enabled its use for both nuclear and optical imaging.

3. Multimodal Imaging
3.1 Importance of Multimodal Imaging
Imaging is a crucial part in the process of diagnosis and treatment, with
which differential diagnosis, lesion detection, evaluation of disease severity and
monitoring of therapeutic efficacy are performed. At present, diverse imaging
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techniques

are

available,

including

optical

imaging,

positron

emission

tomography (PET), single photon emission computed tomography (SPECT),
computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound
(104). However, none of the current imaging methods used in humans provides
comprehensive medical imaging. Combinations of imaging modalities that
integrate the strengths of two modalities, and at the same time eliminate one or
more weaknesses of an individual modality, thus enhance the imaging accuracy
and

provide

complimentary

information

for

improving

diagnostics

and

management of patients (Table 4) (105-110). A common practice today is to
combine techniques with high detection sensitivity such as PET and SPECT with
those with high spatial resolution such as CT, MRI, and ultrasound. For
example, the first fused PET/CT instrument was developed in 1998 by
Townsend and was available commercially in 2001. Its success was such that
by 2003 fused PET/CT instruments were available from all of the major clinical
instrument manufacturers, such as GE, Siemens, and Philips. Over the ensuing
years, PET/CT sales increased with such vigor. Today, there are virtually no
sales of standalone PET instruments and all PET sales are as part of
multimodality systems (109).
Optical imaging methods are the most widely used in preclinical
molecular imaging, whereas nuclear imaging is the most effective clinical
imaging modality. No single imaging modality is perfect. To harness the
strengths of these two different imaging methods, we combined SPECT/CT and
fluorescent optical imaging for detection of apoptosis in this study. Because the
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multimodality imaging techniques can provide complimentary information for
diagnosis, 1 + 1 can add up to more than 2 when it comes to multimodality
imaging systems.

~ 16 ~

3.2 Nuclear Imaging
The radioactive tracer was first introduced in the living system by de
Hevesy and Paneth at 1923 to study metabolism dates. Today, nuclear imaging
techniques such as PET and SPECT, have been an essential part of the
treatment scheme of patients with various diseases. It can be applied to
investigate biological activities (e.g. metabolic rate, transport rate, and binding
capacity) as well as to detect the utilization of an endogenous analogue (e.g. ion,
hormone, and substrate) or the expression of its corresponding biochemical
counterpart (e.g. enzyme, receptor, and transporter) (111-113). Most of radiotracers used in nuclear imaging are based on metabolism, biochemistry and
physiology underlying the process they image. Nuclear imaging can offer high
sensitivity at deep tissue sites and capability of quantification. It is by far the
most effective clinical molecular imaging modality. Owing to the weak spatial
resolution of nuclear imaging, knowing the existence of the abnormality but not
its precise location may decrease their impact on the diagnosis of diseases.
Therefore, multimodal imaging devices such as PET/CT, SPECT/CT, and
PET/MRI, are in development at present, which can produce a final 3dimensional image of biological and anatomical information fused together.
Since no imaging technique is perfect, nuclear imaging also has certain
disadvantages. For example, nuclear imaging may suffer from low photon
counts requiring long scan times as well as from a finite half-life and radiation
dosage preventing longitudinal imaging in patients (114, 115). Moreover, nuclear
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imaging are expensive and do not provide sufficient resolution to image detail in
real time. An alternative is optical imaging.

3.3 Optical Imaging
Optical imaging such as fluorescence and bioluminescence, is an
inexpensive, easily accessible, and non-radiation technique that can be used to
visualize biologic systems at whole-body level as well as at the molecular and
cellular level (116-121). Optical imaging can be carried out noninvasively in real
time, yielding high spatial resolution. Today, optical imaging has become an
active and promising area for in vivo molecular imaging, which makes a
substantial impact on basic science and translational medical research (122,
123). Furthermore, this technique has already entered initial clinical testing in
several areas. For example, diffuse optical spectroscopy of hemoglobin and
deoxyhemoglobin in breast tumors shows promise as a biomarker for effective
neoadjuvant chemotherapy in cancer patients (123, 124).
In vivo optical imaging is based on detection of light passing through
tissues. Thick and opaque tissues can absorb photons and generate strong
autofluorescence, all of which will obscure signal acquisition. However, these
obstacles are less problematic in the near-infrared (NIR) region (650-900nm).
Light in the NIR wavelength region can travel several centimeters through living
tissue. Hemoglobin (the principal absorber of visible light) and water and lipids
(the principal absorbers of infrared light) have their lowest absorption coefficient
in the NIR region. Moreover, most tissues generate little fluorescence in the NIR
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region, which allows improving ratios of target to background in image (125-129).
Recently, 3-dimensional imaging and analysis techniques such as fluorescence
molecular tomography (FMT) have been developed to investigate deep tissues
(e.g. spleen, lung, and liver). FMT can provide 3D volumetric imaging, true
quantification independent of depth, tissue optical properties and heterogeneity,
and augmentation of the contrast by reducing the autofluorescence (125, 127).
This technique will soon be transferred to the clinic for imaging deep events. In
this project, we labeled our imaging tracer with NIR fluorophores (Cyanine 7) for
optical imaging. Cyanine 7, also named as Cy7, is a NIR fluorescent dye that
belongs to the Cyanine family of synthetic polymethine dyes. It is water-soluble,
and has an absorbance maximum of 747 nm and an emission maximum of 776
nm.

4. Nanoparticles
Although our radiotracer (111Indium) and NIR fluorophore (Cyanine 7)
possess excellent imaging properties, neither is tumor specific. To address this
problem, a targeting moiety like nanoparticles, was introduced in this study to
specifically deliver a dual-labeled imaging agent to diseased sites. Nanoparticles
are artificially created materials with dimensions typically smaller than 200 nm.
Because of their unique sizes, nanoparticles fill a critical position between the
macroscopic world and molecular-level detail and can be designed to offer
unique advantages over macroscopic materials and molecular systems (130134). These technological innovations, referred to as nanomedicines by the
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National Institutes of Health, have a potential to turn molecular discoveries
arising from proteomics and genomics into broad benefit for patients. The
development of nanomedicines is beginning to change the foundations of
disease diagnosis, treatment, and prevention (130-134). In the past decades, a
great number of nanoparticles have been developed and some of them showed
a great potential. For example, Abraxane, a nanoparticle version of paclitaxel
bound to albumin, has good water solubility. It has been shown to be much more
effective than previous formulations of paclitaxel, and has already been
approved by the FDA (135, 136).
Nanoparticles have a unique advantage for molecular imaging in which
many functions can be added to the surface and interior of the particle. For
example, multiple diagnostic (e.g., radioisotopic, optical, or magnetic) agents,
targeting ligands, and polyethylene glycol can be attached to nanoparticles, to
provide imaging signal, targeting effect, and alteration of pharmacokinetics.
Recent advances have led to a number of targeting multifunctional nanoparticles
for molecular imaging, drug delivery, and other therapeutic procedures (e.g.
radiotherapy, or phototherapy) (137-142). Moreover, owing to their large surface
area-to-volume ratio, nanoparticles are able to deliver large numbers of imaging
agents per each targeted molecular recognition event to improve sensitivity of
imaging, as well as several different types of imaging agents to perform
multimodality imaging. To sum, with an increasing number of nanoparticle
techiques funded by government, submitted for patents and under review by the
FDA, the outlook for nanoparticle systems in medical application is promising.

~ 20 ~

5. Significance
Apoptosis is critical to homoeostasis, normal development, and
physiology. Abnormal apoptosis is associated with a number of diseases and
therapeutic procedures. It is desirable to have an imaging method to accurately
detect and monitor this process in patients. Therefore, the major goal in this
study is to develop a novel targeting nanoparticle dual-labeled by NIRF optical
dyes and nuclear isotopes for early detection and monitoring of apoptosis. The
novel diagnostic approach potentially permits whole-body visualization to locate
apoptosis by nuclear imaging (e.g. PET or SPECT), followed by fluorescence
imaging guided biopsies to define precisely extent and region of local apoptosis.
According to complimentary diagnostic information, clinicians can accurately
evaluate disease activities and therapeutic outcome. Accurate and rapid
feedback on treatment response will facilitate next phages of therapy. I
anticipate that success of this project will lead to the development of novel
approaches for diagnosis of apoptosis by bringing together advances in
nanotechnology, apoptosis research, and imaging science. Translation of this
discovery from basic science to practical clinic will potentially improve the
efficacy of detection of apoptosis and the management of patients after various
therapeutic interventions.
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MATERIALS AND METHODS

1. Reagents
Common reagents were purchased from Sigma-Aldrich (St. Louis, MO) or
Acros (Geel, Belgium) and used as received unless otherwise specified. Annexin
A5 was obtained from Theseus Imaging Corp. (Cambridge, MA). CCPM
nanoparticle was a kind gift of Carestream Health, Inc. (Rochster, NY). pIsothiocyanatobenzyl-diethylenetriaminepentaacetic acid (DTPA-Bz-NCS) was
purchased from Macrocyclics (Dallas, TX). Indium-111 chloride (111InCl3) was
obtained from Perkin Elmer (Waltham, MA).

2. Synthesis of CCPM Nanoparticles.
CCPM nanoparticles were a kind gift of Carestream Health, Inc.
(Rochester, NY). The reaction scheme for synthesis of CCPM nanoparticles is
shown in Figure 5. The detailed procedure for synthesis of CCPM nanoparticles
was described below. (Reprinted with permission of (143))
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Figure 5. Synthesis of PPEGMA-b-PESPMA block copolymer and schematic
illustration of the preparation of amine-terminated, core-crosslinked polymeric
micelles containing NIRF dyes. (Reprinted with permission of (143))

2.1 Analytical Methods
1

H and 13C NMR spectra were recorded on a Varian XL-300 spectrometer

(Varian, Inc., Palo Alto, CA) operating at 300 MHz with tetramethyl silane (TMS)
as an internal standard. Molecular weights were determined with gel permeation
chromatography (GPC) using poly(methyl methacrylate) with narrow molecular
weight distribution as standards. The samples were separated using two 7.5 ×
300 mm PLgel mixed-C columns (Polymer Laboratories, Amherst, MA) eluted
with 1,1,1,3,3,3-hexafluoroisopropanol containing 0.01 M tetraethyl ammonium
nitrate at a flow rate of 1.0 mL/min. Particle size was measured using dynamic
light scattering with a Malvern ZetaSizer Nano-ZS system (Malvern Instruments
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Ltd, Worcestershire, UK). Zeta potential was determined using a ZetaPlus
Analyzer (Brookhaven Instruments Corp., Holtsville, NY).

2.2 2-Aminoethyl 2-Bromoisobutyrate
A solution of t-Boc-aminoethyl alcohol (50 g, 0.31 mol) and triethylamine
(34.5 g, 0.34 mol) in 300 mL of methylene chloride was cooled in an ice bath.
Into the solution was added 2- bromoisobutyryl bromide (71.3 g, 0.31 mol) in 150
mL of methylene chloride. The reaction was slowly warmed to room temperature
and stirred for 4 h. The salt was filtered off and the reaction mixture was
extracted sequentially with water and saturated sodium bicarbonate solution.
The organic phase was dried over magnesium sulfate. Solvent was evaporated
and the crude product was purified by column chromatography using
heptane/diethyl ether (80/20, w/w) as an eluent to give 65 g of t-Boc-aminoethyl
2-bromoisobutyrate as a white solid (yield 92%). 1H NMR (CDCl3) δ (ppm): 1.45
(s, 9 H), 1.95 (s, 6 H), 3.42–3.48 (m, 2 H), 4.24 (t, J = 5.25 Hz, 2 H). t-Bocaminoethyl 2-bromoisobutyrate (5.00 g, 0.016 mol) was treated with 15 mL of
trifluoroacetic acid under vigorous stirring to remove the t-Boc protection group.
After the reaction, excess trifluoroacetic acid was removed and the crude
product was dried under a vacuum overnight. The crude product was stirred with
a mixture of hexane and ethyl acetate and filtered to give 3.18 g of trifluoroacetic
acid salt of 2-aminoethyl 2-bromoisobutyrate as a white crystalline powder (yield
94%). 1H NMR (CDCl3) δ (ppm): 1.93 (s, 6 H), 3.35 (s, br, 2 H), 4.46 (t, J = 5.1
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Hz, 2 H), 8.10 (s, br, 3 H); 13C NMR (CDCl3) δ (ppm): 30.24, 38.76, 55.52, 61.99,
161.49, 161.96, 162.43, 162.90, 171.78.

2.3 Block Copolymer PPEGMA-b-PESPMA (x = 31, y = 46)
A 50-mL 3-neck flask was equipped with an additional funnel, a stopper,
and a septum. Trifluoroacetic acid salt of 2-aminoethyl 2-bromoisobutyrate
(0.106 g, 0.33 mmol) and bipyridine (174 mg, 1.11 mmol) were dissolved in 2.4
mL of dry methanol in the flask, and methoxy-PEG methacrylate (PEG-MA, MW
475) (4.8 g, 0.01 mol) was added. Triethoxysilylpropyl methacrylate (ESP-MA)
(vacuum distilled from CaH2) (4.5 mL, 4.41 g, 0.015 mol) was placed in the
additional funnel with 2.0 mL of dry methanol. Both mixtures in the flask and
additional funnel were degassed by bubbling nitrogen for 15 min. Then CuBr (80
mg, 0.56 mmol) was added quickly to the flask, and the solution turned dark
brown. The flask was heated in an oil bath at 50°C for 30 minutes and ESP-MA
solution was added quickly to the flask. The polymerization was continued
overnight at 50°C. The polymerization mixture was then diluted with dry THF,
passed through a pad of celite and basic aluminum twice, and concentrated to
yield a clear, viscous semi-solid. 1H NMR indicated the ratio of x/y to be close to
1/1.5. 1H NMR (300 MHz, CDCl3) δ (ppm): 0.55 (s, br), 0.77 (s, br), 0.95 (s, br),
1.18 (t, CH3 from Si (OCH2CH3)), 1.64 (s, br), 1.96 (s, br), 3.31 (s, OMe), 3.58 (s,
br, PEG), 3.75 (m, CH2 from Si(OCH2CH3)), 4.01 (s, br).

~ 25 ~

2.4 CCPM Nanoparticles
The overall process consisted of two steps. Polymeric micelles were first
formed upon the gradual addition of distilled water into a THF solution of the
block copolymer and Cy7-like dye 3-(triethoxysilyl)propyl-Cy7. This was followed
by the addition of acetic acid to induce a crosslinking reaction among ethoxysilyl
groups. Briefly, block copolymer PPEGMA-b-PESPMA (100 mg) and 3(triethoxysilyl) propyl-Cy7 (0.4 mg) were dissolved in 10 mL of THF. 10 mL of
distilled water was then added slowly to the THF solution. The mixture was
stirred at room temperature in the dark for 8 h, 0.05 mL acetic acid was added,
and the mixture was stirred again at room temperature overnight. For
purification, the nanoparticle-containing solution was dialyzed against distilled
water for 24 h (MW cutoff, 3000). The solution was then filtered sequentially
through 0.7, 0.45, 0.2, and 0.1 μm filters. The solution could be concentrated to
the desired concentration by centrifugal filtration using a membrane with a
molecular weight cutoff of 30,000.

2.5 DTPA-Conjugated CCPM Nanoparticle
An aqueous solution of CCPM nanoparticles (20 mL, 9.3 mg dry
weight/mL water) was placed in an amber vial. The pH of the solution was
adjusted to 7.5 using 2% sodium bicarbonate solution. DTPA-Bz-NCS (0.6 mg, 1
mg/mL water) was added to the vial. The reaction was stirred under nitrogen
overnight. Unreacted DTPA-Bz-NCS was removed by centrifugal filtration using
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a membrane with a molecular weight cutoff of 30,000. Approximately 70% of the
DTPA used was attached to the particles.

3. Annexin A5-Conjugated CCPM
3.1 Conjugation of Annexin A5 to CCPM

Figure 6. Reaction scheme for the conjugation of annexin A5 to CCPM and
radiolabeling of the resulting annexin A5-CCPM. (Reprinted with permission of
(144))

The reaction scheme for the conjugation of annexin A5 to the surface of
CCPM is shown in Figure 6. To introduce maleimide group to CCPM, an aliquot
of N-[γ-maleimidobutyryloxy]-succinimide ester (GMBS) in dimethylformamide
(22.5 µL, 7 µmol/mL, 0.16 µmol) was added into CCPM (250 µL, 2.6 nmol
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nanoparticles) in 1.2 mL of phosphate-buffered saline (PBS, pH 8). The mixture
was stirred for 3 h at 37°C. The product was purified using a PD-10 column to
remove unreacted GMBS. To introduce sulfhydryl group to annexin A5, an
aliquot of N-succinimidyl S-acetylthioacetate in dimethyl sulfoxide (26.4 µL, 50
nmol/mL, 1.3 µmol) was added into annexin A5 (2.4 mg, 0.06 µmol) in 4.5 mL of
PBS (pH 8). The mixture was stirred for 12 h at 4°C, and then hydroxylamine in
water (0.5 mL, 0.5 M) was added to the solution to remove the protecting group.
The reaction mixture was stirred for an additional 2 h and was concentrated to 1
mL by ultracentrifugation (MWCO, 10K; Millipore Corp., Bedford, MA). After
being passed through a PD-10 column to remove small-molecular-weight
contaminants, the resulting sulfhydryl-containing annexin A5 was mixed with 2
mL of PBS solution of CCPM-maleimide (0.16 µmol equivalent maleimide) with a
molar ratio of annexin A5 to maleimide groups (CCPM) of 1:2. The solution was
stirred for 12 h at 4°C and then purified using a fast protein liquid
chromatography system (Amersham Pharmacia Biotech, Sweden) equipped
with a G200 column and an ultraviolet light detector (280 nm). The column was
eluted with PBS to remove unreacted annexin A5. The unreacted annexin A5
was quantified using a protein assay kit (Bio-Rad, Hercules, CA) according to
the manufacturer’s protocol, and the data were used to calculate the molar ratio
of annexin A5 bound to CCPM in annexin A5-CCPM.
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3.2 Characterization of Annexin A5-CCPM.
For transmission electron microscopic examination, a drop of aqueous
sample solution was placed on a 400-mesh copper grid coated with 0.5%
poly(vinyl formal) aqueous solution (w/w). Negative staining was performed
using a droplet of 1% uranyl acetate solution. The sample was air-dried and
examined with a JEM 1010 transmission electron microscope (JEOL USA, Inc.,
Peabody, MA) at an accelerating voltage of 80 kV. Digital images were obtained
using the AMT Imaging System (Advanced Microscopy Techniques Corp.,
Danvers, MA). Fluorescence spectra were recorded using a Fluorolog
fluorometer (Horiba, Edison, NJ).

4. Radiolabeling.
Aliquots of annexin A5-CCPM in 0.1 M sodium acetate solution (pH 5.2)
were mixed with an aqueous solution of
Radiolabeled

nanoparticles

were

111

InCl3 at room temperature for 30 min.

analyzed

using

an

instant

thin-layer

chromatography system. The instant thin-layer chromatography strips were
developed with PBS (pH 7.4) containing 4 mM EDTA and quantified using a
Bioscan IAR-2000 TLC Imaging Scanner (Washington, DC). Free

111

In3+ moved

to the solvent front (Rf = 0.9), and the nanoparticles remained at the original
spot (Rf = 0.0).
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5. Cell Culture
DLD-1 human colorectal adenocarcinoma cells, EL4 murine lymphoma
cells, 38C13 murine lymphoma cells, 9L rat gliosarcoma cells, and MDA-MB468
human breast cancer cells, were obtained from American Type Cell Culture
(Rockville, MD). Cells were maintained at 37°C in a humidified atmosphere
containing 5% CO2 in Dulbecco’s modified Eagle’s medium and nutrient mixture
F-12 Ham (DMEM/F12) (Gibco, Carlsbad, CA) supplemented with 10% fetal calf
serum and a mixture of antibiotics (100 units mL-1 penicillin, 0.1 mg mL-1
streptomycin; Biochrom AG, Holliston, MA).

6. Fluorescence Microscopy
DLD-1 human colorectal adenocarcinoma cells were treated with tumor
necrosis factor-related apoptosis-inducing ligand (TRAIL) (Sigma-Aldrich) (200
µL, 150 ng/mL) for 2 h to induce apoptosis. The cells were then incubated with
annexin A5-CCPM or annexin A5-CCPM plus annexin A5 (100-fold excess) in
HEPES binding buffer (25 mM HEPES, 140 mM NaCl, and 2.5 mM CaCl2, pH
7.4) for 15 min at 37°C at a final concentration of 20 nM nanoparticles.
Untreated DLD-1 cells were used as a control. Cells were washed 3 times with
HEPES binding buffer and cell membrane stained with wheat germ agglutininAlexa Fluor 594 (Invitrogen, Carlsbad, CA). The cell samples were transferred
onto Lab-Tek II chambered cover glass and visualized under a Zeiss Axio
Observer.Z1 fluorescence microscope (Carl Zeiss MicroImaging GmbH,
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Thornwood, NY) equipped with Cy7 filters (wavelength 710/810 nm) and
rhodamine filters (wavelength 570/620 nm).

7. Cell Binding Study
To study cell uptake of

111

In-labeled annexin A5-CCPM, DLD-1 cells were

grown in 6-cm petri dishes to subconfluent densities in DMEM/F12 containing 10%
fetal bovine serum 1 day before experiments. DLD-1 cells were treated with
TRAIL at doses of 1.5 ng/mL, 15 ng/mL, and 150 ng/mL for 2 h to induce
apoptosis. After treatment with TRAIL, the medium was replaced with 2 mL of
fresh medium containing

111

In-labeled annexin A5-CCPM nanoparticles (~1.8

MBq/mL), and cells were incubated for 15 min. The cell monolayers were
scraped and transferred into 5-mL tubes, and the tubes were briefly vortexed.
Aliquots of DLD-1 cell suspension (100 µL) were transferred into a
microcentrifuge tube containing 500 µL of a 75:25 mixture of silicon oil (density
1.05, Aldrich) and mineral oil (density 0.872, Acros). The mixture was
centrifuged at 14,000 rpm for 5 min. After the tubes were frozen with liquid
nitrogen, the bottom tips containing the cell pellet were cut off. The cell pellets
and the supernatants were counted with a γ-counter (Perkin-Elmer). The protein
content in 100 μL of cell suspension was quantified in a separate experiment
using a Bio-Rad protein assay kit according to the manufacturer’s protocol.
Activity ratios of the cell pellet to medium ([cpm/µg of protein in pellet]/[cpm/µg of
medium]) were calculated. The experiments were performed in pentaplicate. In a
separate study, aliquots of DLD-1 cell suspension (500 µL) after TRAIL
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treatment were transferred into microcentrifuge tubes, annexin A5-fluorescein
isothiocyanate (FITC) was added to the tubes, and the percentage of apoptotic
cells was analyzed using a Becton-Dickinson FACSCalibur flow cytometer (BD
Biosciences, San Jose, CA).

8. Red Blood Cell Binding Study
Membrane lipid scrambling of red blood cell (RBC) was induced by
calcium and ionophore treatment as described by Kuypers (145). Briefly, RBCs
were first equilibrated in the buffer with1 mmol/L calcium for 5 min at 37°C
before experiment. Then RBCs were incubated with calcium and ionophore with
a concentration of 4 pmol/L for 1 h. After incubation, RBCs were washed once
with 2.5 mmol/L EDTA to remove calcium, and then washed 3 times with
HEPES buffer containing 1 % bovine serum albumin (BSA) to remove ionophore.
RBCs were suspended in HEPES buffer to a final concentration of 5 X 106 /mL
for annexin A5-CCPM binding study. Aliquots of RBC suspension (100 µL) were
incubated with

111

In-labeled annexin A5-CCPM in HEPES binding buffer (25 mM

HEPES, 140 mM NaCl, and 2.5 mM CaCl2, pH 7.4) for 30 min at room
temperature, at a final concentration of 100 nM, 200 nM, 300 nM, 400 nM, 500
nM, and 600 nM nanoparticles. In the blocking group, aliquots of RBC
suspension (100 µL) were co-incubated with

111

In-labeled annexin A5-CCPM at

above 6 concentrations and cold annexin A5 (100-fold excess). After incubation,
the samples were centrifuged at 14,000 rpm for 10 min. The cell pellets were
subsequently washed 3 times with HEPES buffer to remove unbound annexin
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A5-CCPM and counted with a γ-counter (Perkin-Elmer). Radioactivity counts
(cpm) of the cell pellets were calculated and plotted against concentration. The
experiment was performed in triplicate.

9. Pharmacokinetic Study
All animal studies were carried out in the Small Animal Imaging Facility at
The University of Texas MD Anderson Cancer Center in accordance with
institutional guidelines. For the pharmacokinetic study, healthy female Swiss
mice (22–25 g; Charles River Laboratories, Wilmington, MA) (n = 8) were
injected intravenously at a dose of 5 × 1013

111

In-labeled annexin A5-CCPM or

111

In-labeled plain CCPM per mouse (1.8 MBq/mouse). At predetermined

intervals, blood samples (10 μL) were taken from the tail vein, and the
radioactivity of each sample was measured with a Cobra Autogamma counter
(Packard, Downers Grove, IL). The blood pharmacokinetic parameters for the
radiotracer were analyzed using a noncompartmental model with WinNonlin
5.0.1 software (Pharsight Corp., Palo Alto, CA).

10. EL4 lymphoma Apoptosis Model
Apoptosis of EL4 lymphoma was induced as described previously (10).
Briefly, EL4 cells (1.0 x 106) were inoculated subcutaneously in the right flank of
6- to 8-week-old syngeneic C57BL/6 mice. Two weeks after inoculation, when
tumors reached approximately 5-6 mm in diameter, mice were divided into 4
groups. Mice in group 1, 3, and 4 were given intraperitoneal injection of 25
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mg/kg cyclophosphamide and 19 mg/kg etoposide. Mice in group 2 were not
treated and were used as a control group. Mice in groups 1 and 2 received
intravenous injection of

111

In-labeled annexin A5-CCPM 1 day after drug

treatment (n = 7 per group). Mice in group 3 received
mice in group 4 received

99m

Tc-HYNIC-annexin A5,

111

In-labeled CCPM 1 day after drug treatment (n = 5

per group). At 48h after administration of

111

In-labeled annexin A5-CCPM, mice

in group 1 and 2 underwent a series of studies, including radionuclide imaging,
optical imaging, biodistribution, autoradiography and histological analysis.
In comparison the uptake value of in apoptotic tumor, mice in group 3
injected with

99m

Tc-HYNIC-annexin A5 were killed at 6 h after radiotracer

injection, and mice in group 4 injected with

111

In-labeled CCPM were killed at 48

h after administration of particles.

11. 38C13 lymphoma Apoptosis Model
Apoptosis of 38C13 murine lymphoma was induced as described
previously (11). Briefly, 38C13 cells (1.0 x 106) were inoculated subcutaneously
in the right flank of 6–8 week-old female C3H/ HeNCrl mice (22–25 g; Charles
River Laboratories, Wilmington, MA). Two weeks after inoculation when tumors
reached 5~6 mm in diameter, mice were divided to two groups (n = 6 per group).
Mice in the chemotherapy group were given intraperitoneal injection of 100
mg/kg cyclophosphamide. Mice in the control group were untreated.

111

In-

labeled annexin A5-CCPM (1 × 1014 particles/mouse, 9.2 MBq/mouse) was
injected intravenously via the tail vein 1 day after drug treatment. At 48 h after
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administration of

111

In-labeled annexin A5-CCPM, the mice underwent a series

of studies, including radionuclide imaging, optical imaging, biodistribution,
autoradiography and histological analysis.

12. 9L Gliosarcoma Tumor Apoptosis Model
Induction of apoptosis in 9L gliosarcoma tumor model was achieved as
described previously (12). Briefly, 9L rat gliosarcoma cells (1.0 x 106) were
inoculated subcutaneously in the right flank of 6- to 8-week-old female nude
mice. Three weeks after inoculation, when tumors reached approximately 5-6
mm in average diameter, mice were divided into 2 groups (n = 6 per group).
Mice in chemotherapy group were given intraperitoneal injection of 170 mg/kg
cyclophosphamide. Mice were not treated as a control group.

111

In-labeled

annexin A5-CCPM (1 × 1014 particles/mouse, 9.2 MBq/mouse) was injected
intravenously via the tail vein 1 day after the injection of cyclophosphamide. At
48 h after administration of
a

series

of

studies,

111

In-labeled annexin A5-CCPM, the mice underwent

including

radionuclide

imaging,

optical

imaging,

biodistribution, autoradiography and histological analysis.

13. MDA-MB-468 Breast Tumor Apoptosis Model
Induction of apoptosis in an MDA-MB-468 breast cancer model was
achieved as described previously (13). Briefly, MDA-MB-468 human breast
cancer cells (1 x 106) were inoculated subcutaneously in the right flank of 6- to
8-week-old female nude mice. Four weeks after inoculation, when tumors
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reached approximately 5-6 mm in average diameter, mice were divided into 2
groups (n = 2 per group). Mice in group 1 were given a single intravenous
injection of poly(L-glutamic acid)-paclitaxel at a dose of 100 mg eq. paclitaxel/kg
on day 1 and a single intraperitoneal injection of cetuximab (Imclone Systems,
New York, NY), a monoclonal antibody directed against epidermal growth factor
receptor, at a dose of 1 mg on day 4. Mice in group 2 were not treated and were
used as a control group.

111

In-labeled annexin A5-CCPM (1 × 1014

particles/mouse, 9.2 MBq/mouse) was injected intravenously via the tail vein 1
day after the injection of cetuximab. At 48 h after administration of

111

In-labeled

annexin A5-CCPM, the mice underwent a series of studies, including
radionuclide imaging, optical imaging, autoradiography and histological analysis.

14. Hepatic Apoptosis Model
Induction of hepatic apoptosis was achieved as described (14). Healthy
female BALB/c mice (22–25 g; Charles River Laboratories, Wilmington, MA)
were divided into 3 groups (n=7 per group). Mice in group 1 and 3 were injected
intravenously with a purified anti-Fas monoclonal antibody (10 µg/mouse, Jo2,
Pharmingen, San Diego, CA). The mice in group 2 injected with PBS were used
as a control group. One and half hour after administration of anti-Fas antibody or
PBS, Mice in group 1 and 2 received intravenous administration of

111

In-labeled

annexin A5-CCPM. To further assess the binding specificity, mice in group 3
treated with anti-Fas antibody were injected intravenously with

111

CCPM as another control. At 3 h after administration of

111
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In-labeled
In-labeled

nanoparticles, the mice underwent a series of studies, including radionuclide
imaging, optical imaging, biodistribution, autoradiography and histological
analysis.

15. Inflammation Model
Healthy female SWISS mice (22–25 g; Charles River Laboratories,
Wilmington, MA) received a deep intramuscular injection of 100 µL of 100% pure
gum turpentine (Spectrum, New Brunswick, NJ) in the right thigh of mice. The
left thigh served as an internal control for nonspecific thigh uptake of tracer. Mice
were divided into 2 groups (n=5 per group). In group 1, at 24 h after the
administration of turpentine,

111

In-labeled annexin A5-CCPM was injected

intravenously. Mice in group 2 were injected with
control. At 48 h after administration of

111

In-labeled CCPM as another

111

In-labeled nanoparticles, the mice

underwent a series of studies, including radionuclide imaging, optical imaging,
biodistribution, autoradiography and histological analysis.

16. Imaging and Biodistribution Studies
In above 6 models, at respective time point after administration of

111

In-

labeled annexin A5-CCPM or CCPM nanoparticles, single photon computed
tomography (SPECT) and computed tomography (CT) images were acquired
using an xSPECT-CT scanner (Gamma Medica, Northridge, CA). SPECT
(radius of rotation 3 cm, 32 projections, 20 s per projection) and CT scans (512
projections, 75 kV, 500 mA) were acquired and co-registered for image fusion
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and presentation of 3D anatomical localization of the tracer signal. Acquired
SPECT and CT data sets were processed with AMIRA 5.1 (San Diego, CA). The
whole-body optical imaging was performed using fluorescent molecular
tomography

(FMT,

Visen,

Bedford,

MA)

equipped

with

760/790

nm

excitation/emission wavelength filter. During each imaging session, mice were
anesthetized with 2% isoflurane gas (Iso-Thesia, Rockville, NY) in oxygen.
By the end of the imaging sessions, mice were killed, and various tissues
were removed, weighed, and counted for radioactivity with a Cobra Autogamma
counter (Packard, Downers Grove, IL). Uptake of the nanoparticles was
calculated as the percentage of the injected dose per gram of tissue (%ID/g).
Additionally in EL4 lymphoma apoptosis model, fluorescence images of dissected
tissues were acquired using an IVIS imaging system (Xenogen Corp., Alameda, CA)
equipped with indocyanine green filter sets (excitation/emission, 710-760/810-875 nm).
Fluorescence intensities were calculated using LIVINGIMAGE v.2.11 software
(Xenogen). Uptakes of the nanoparticles in various tissues were calculated as flux
(photons/s) per gram of tissue. Student’s t test was used to compare differences in

tissue uptakes between different groups, and p values less than 0.01 were
considered highly significant.

17. Autoradiography and Optical Imaging
Tumors harvested at the end of the imaging sessions were snap-frozen
and sectioned into 5-µm sections. The sections were photographed and
exposed on BAS-SR 2025 Fuji phosphorous films. The film was scanned with a
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FLA5100 Multifunctional Imaging System (Fujifilm Medical Systems USA,
Stamford, CT).
After autoradiographic study, optical images of the sections were
acquired by scanning at 800 nm using an Odyssey infrared imaging system (LICOR Biosciences, Lincoln, NE).

18. Immunohistochemistry
In EL4 and 38C13 lymphoma models, following autoradiographic study,
one slice of each tumor was immunostained with anti-caspase-3 antibody by
using a commercial kit (Sigma, St. Louis, MO) according to the manufacturer’s
protocol. The stained sections were counterstained with hematoxylin. Image was
recorded by a Zeiss Axio Observer.Z1 microscope.
In all 4 tumor apoptosis models, for terminal deoxynucleotidyl transferase
dUTP nick end labeling (TUNEL), a slide adjacent to those used for
autoradiographic studies was stained with a TUNEL staining kit (R&D Systems,
Minneapolis, MN) according to manufacturer’s instruction. Cell nuclei were
counterstained

with

4'-6-Diamidino-2-phenylindole

(DAPI).

The

cellular

fluorescence was examined under a Zeiss Axio Observer.Z1 fluorescence
microscope equipped with UV filter for DAPI, 494/517 nm filter for TUNEL
staining, and 710/810 nm for Cy7.
In the models of hepatic apoptosis and inflammation, following
autoradiographic study, one slice of each tissue (liver or thigh) received
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Hematoxylin and Eosin (H&E) staining. Image was recorded by a Zeiss Axio
Observer.Z1 microscope.

19. Statistical Analysis
Statistical analysis was performed with GraphPad Prism v4.0 software
(La Jolla, CA). Unless otherwise stated, group comparisons were made using
standard ANOVA methods. Groups with P < 0.01 were considered highly
significant.
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RESULTS

1. Characterization of CCPM Nanoparticles
Table 5 showed physicochemical properties of CCPM nanoparticles.
According to previous report by Dr. Zhi Yang (143), each CCPM nanoparticle
contained approximately 21 Cy7-like dye molecules, 180 amino (NH2) groups
and 19 DTPA molecules.

Table 5. Summary of physicochemical properties of CCPM nanoparticles.
(Reprinted with permission of (143))

2. Characterization of Annexin A5-CCPM Nanoparticles
Figure 7A is a transmission electron microscopic image of annexin A5CCPM. The excitation and emission light intensities for the annexin A5-CCPM
nanoparticles peaked at 755 nm and 781 nm, respectively (Fig. 7B). The
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average diameter of the nanoparticles was 25 nm on the basis of transmission
electron microscopy images. After purified using FPLC (Fig. 7D), each annexin
A5-CCPM nanoparticle contained approximately 40 annexin A5 molecules on
the surface calculated on the basis of the molar feed ratio. As indicated by
instant thin-layer chromatography, the labeling efficiency of annexin A5-CCPM
was greater than 98% without further purification (Fig. 7C). The specific activity
was 185 MBq/nmol nanoparticles.

Figure 7. Characterization of annexin A5-CCPM nanoparticles. (A)
Transmission electron micrograph of annexin A5-CCPM nanoparticles. (B)
Absorbance and emission spectra of CCPM before and after introduction of
annexin A5. (C) ITLC result of 111In-labeled annexin A5-CCPM. (D) FPLC result
of annexin A5-CCPM after purification.

~ 42 ~

3. Fluorescence Microscopy

Figure 8. Fluorescence microphotographs of DLD-1 human colon cancer cells
after exposure to annexin A5-CCPM. DLD-1 cells were treated with TRAIL (150
ng/mL) followed by 111In-labeled annexin A5-CCPM 2 h later (left); TRAIL
followed by 111In-labeled annexin A5-CCPM plus annexin A5 (100-fold excess) 2
h later (middle); or PBS followed by 111In-labeled annexin A5-CCPM 2 h later
(right). Signal from Cy7-loaded CCPM is pseudocolored green. Cell membrane
was stained with Alexa Fluor 594-labeled wheat germ agglutinin (WGA) (red),
and cell nuclei were stained with DAPI (blue).
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Figure 8 shows fluorescence microscopic images of viable human DLD-1
colon cancer cells and apoptotic DLD-1 cells incubated with annexin A5-CCPM.
The membrane of both TRAIL- and PBS-treated cells was stained red with
wheat germ agglutinin-Fluor594. However, only TRAIL-treated cells showed
binding of annexin A5-CCPM to the cell membrane. Moreover, the binding of
annexin A5-CCPM to the apoptotic cells was efficiently blocked by annexin A5
(Fig. 8).

4. Cell Binding Study
TRAIL-induced apoptosis in DLD-1 cells was analyzed by flow cytometry
at TRAIL concentrations of 1.5-150 ng/mL using FITC-annexin A5 (Fig. 9A).
There was a sharp increase in the apoptotic response when TRAIL
concentration increased from 15 to 150 ng/mL, and the percentage of apoptotic
cells increased from 3.76% to 24.5%. When

111

In-labeled annexin A5-CCPM

was incubated with TRAIL-treated DLD-1 cells, increasing amount of the
radiotracer was bound to the cells in a TRAIL dose-dependent manner (Fig. 9B).
A significant increase in cell-associated radioactivity was detected at a TRAIL
dose of 1.5 ng/mL. The binding of

111

In-labeled annexin A5-CCPM to apoptotic

cells was completely blocked by an excess of annexin A5 (Fig. 9B). These
results confirmed that

111

In-labeled annexin A5-CCPM selectively bound to PS

on the surface of apoptotic cells.
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Figure 9. Uptake studies of DLD-1 human colon cancer cells after exposure to
111
In-labeled annexin A5-CCPM. (A) DLD-1 cells were incubated with TRAIL for
2 h at the indicated doses, stained with annexin A5-FITC, and assayed for the
percentage of apoptotic cells using flow cytometry. (B) DLD-1 cells were
incubated with TRAIL for 2 h at the indicated doses and then incubated with
111
In-labeled annexin A5-CCPM without or with annexin A5 (100-fold excess) for
15 min. The data are expressed as cpm/µg protein in cell pellet over cpm/µg
medium and presented as mean ± standard deviation (n = 5). * Indicates
statistically significant change in values with P <0.001.
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5. Red Blood Cell Binding Study
It has been reported that radioactive or fluorescent annexin A5 could be
used as a probe to detect RBCs that have lost phospholipid asymmetry (145).
Figure 10 showed that binding curves of

111

In-labeled annexin A5-CCPM to

RBCs without and with excess annexin A5. When

111

In-labeled annexin A5-

CCPM was incubated with RBCs, increasing amounts of the nanoparticles
bound to the cells in a dose-dependent manner. In contrast, little binding to
RBCs was detected in the presence of excess annexin A5, suggesting that the
binding was efficiently blocked by excess amount of annexin A5.

Figure 10. The binding study of 111In-labeled annexin A5-CCPM to RBCs. RBCs
were incubated with 111In-labeled annexin A5-CCPM at the indicated doses
without or with annexin A5 (100-fold excess) for 30 min. The data are expressed
as radioactivity counts (cpm) of cell pellets and presented as mean ± standard
deviation (n = 3).
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6. Pharmacokinetics

Figure 11. Blood activity-time profiles of 111In-labeled annexin A5-CCPM and
plain CCPM. The open circles represent the mean radioactivity expressed as a
percentage of the injected dose per gram of blood from 7 mice. Data for CCPM
were taken from reference (143).

Figure 11 compares the activity-time profiles of

111

In-labeled annexin A5-

CCPM and plain CCPM. Data for CCPM were taken from reference (143). The
plain CCPM showed a bi-exponential disposition, whereas

111

In-labeled annexin

A5-CCPM appeared to have a single exponential disposition following
intravenous administration. Mean pharmacokinetic parameters are summarized
in Table 6. Introduction of annexin A5 to CCPM resulted in a significantly shorter
mean terminal elimination half-life, less systemic exposure (total area-under-thebloodconcentration versus time curve), and smaller mean volume of distribution
at steady-state as compared with unmodified CCPM. The mean systemic
clearance was significantly slower with the unmodified CCPM (0.0902 mL/h)
than with

111

In-labeled annexin A5-CCPM (0.217 mL/h, P <0.001), suggesting
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that

111

In-labeled annexin A5-CCPM was cleared more than twice as fast as the

unmodified CCPM. This can be attributed to higher elimination by the liver
and/or spleen of

111

In-labeled annexin A5-CCPM than of CCPM. For both

111

In-

labeled CCPM and annexin A5-CCPM, mean volume of distribution at steadystate was similar to mean volume of distribution in the central compartment,
indicating that both agents mainly distributed to the central compartment
(systemic blood circulation).
Parametera

CCPM

Annexin A5-CCPM

P

8

7

-

T1/2 (h)

39.0 ± 8.4

12.5 ± 1.4

0.000

AUC (%ID/mL blood)

1148 ± 213

466 ± 53

0.000

Cmax (%ID/mL)

27.2 ± 3.1

22.4 ± 2.9

0.008

Vd (mL)

4.95 ± 0.9

3.91 ± 0.64

0.024

Vss (mL)

5.18 ± 0.65

4.44 ± 0.24

0.015

0.0902 ± 0.019

0.217 ± 0.023

0.000

58.7 ± 8.3

20.6 ± 1.9

0.000

Number of mice

CL (mL/h)
MRT (h)

Table 6. Comparison of mean ± standard deviation pharmacokinetic parameters for
plain CCPM and 111In-labeled annexin A5-CCPM in mice. aT1/2 = terminal biological halflife; AUC = total area under the blood concentration versus time curve; Cmax = predicted
maximum drug concentration in blood; %ID = percentage of injected dose; Vd =
apparent volume of distribution; Vss = steady-state volume of distribution; CL = total
body clearance; MRT = mean residence time. P values were obtained using a 2sample t test.
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7. EL4 Lymphoma Apoptosis Model
Treatment of mice bearing EL4 lymphoma with cyclophosphamide and
etoposide induces substantial apoptosis (10). This model was used to study the
111

effect of apoptosis on the biodistribution of

In-labeled annexin A5-CCPM.

Figure 12 compares µSPECT and fluorescent molecular tomography optical
images of mice with and without treatment of cyclophosphamide/etoposide
regimen obtained 48 h after administration of

111

In-labeled annexin A5-CCPM.

The apoptotic tumor was clearly visualized after chemotherapy in these mice
with EL4 lymphoma (Figs. 12A and 12B). In contrast, there was little signal in
the tumors of untreated mice (Figs. 14A and 12B). Intratumoral distribution of
111

In-labeled annexin A5-CCPM was shown in both autoradiographic images

(Fig. 12C) and fluorescence optical images of tumor sections (Fig. 12D).
Chemotherapy caused markedly increased radioactivity and fluorescent signal
intensity in the tumors. Localization of both radioactivity and fluorescence signal
from

111

In-labeled annexin A5-CCPM correlated with apoptotic cells stained with

caspase-3 antibody (Figs. 12C-12F). Moreover, fluorescence microscopy
showed that the fluorescent signal from

111

In-labeled annexin A5-CCPM co-

localized with apoptotic cells detected with TUNEL assay (Fig. 13).
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Figure 12. Dual SPECT/CT and near-infrared fluorescence optical imaging of
EL4 lymphoma apoptosis with 111In-labeled annexin A5-CCPM. The mice in the
control group (top) were injected intravenously only with 111In-labeled annexin
A5-CCPM. The mice in the chemotherapy group (bottom) received an
intravenous injection of 111In-labeled annexin A5-CCPM 24 h after treatment with
cyclophosphamide 25 mg/kg by intraperitoneal (i.p.) injection and etoposide 19
mg/kg by i.p. injection. (A) Representative SPECT/CT images. (B)
Representative fluorescence molecular tomographic images. (C) Representative
autoradiographs of excised tumors. (D) Fluorescence images of the same slides
used in autoradiographic studies. (E and F) Immunohistochemical staining with
caspase-3 (brown) of the same slides used in autoradiographic studies. All
images were acquired 48 h after injection of 111In-labeled annexin A5-CCPM.
Bar, 50 µm.
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Figure 13. Fluorescence microscopy of EL4 lymphoma from mice treated with
chemotherapy. The tumor sections were subjected to TUNEL staining (red).
Signal from Cy7 loaded annexin A5-CCPM was pseudocolored green and cell
nuclei were stained with DAPI (blue). Scale bar: 50 µm.
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The biodistribution data (Fig. 14A) were generally in concordance with
the imaging result (Fig. 12): there was relatively high accumulation in the liver
and spleen. Spleens of the mice treated with chemotherapy showed significantly
higher uptake of

111

In-labeled annexin A5-CCPM than spleens in the control

group (P <0.001), probably owing to cyclophosphamide-induced apoptosis of
this tissue (83). At 48 h after injection,

111

In-labeled annexin A5-CCPM showed

significantly higher uptake in the tumors of the treated mice (8.01 %ID/g) than in
the tumors of the untreated mice (3.2 %ID/g) (P <0.001) (Fig. 14A). The tumorto-blood ratios were 2.2 in the untreated group versus 4.1 in the chemotherapytreated group, and the tumor-to-muscle ratios were 14.8 in the untreated group
versus 38.8 in the chemotherapy-treated group.

111

In-labeled annexin A5-CCPM

(8.01 %ID/g) also showed significantly higher uptake in the tumors of the treated
mice than

99m

Tc-HYNIC annexin A5 (4.14 %ID/g) and

111

In-labeled CCPM

(2.81 %ID/g) (P <0.001) (Fig. 14B). The biodistribution was also determined by
analysis of fluorescence signal intensities of the resected tissues (Fig. 15),
which were consistent with the data obtained by the radioactivity count method
(Fig. 14A).
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Figure 14. Biodistribution in mice bearing EL4 lymphoma. (A) Biodistribution 48
h after the administration of 111In-labeled annexin A5-CCPM. The mice in the
chemotherapy group were injected with 111In-labeled annexin A5-CCPM
intravenously 24 h after administration of cyclophosphamide and etoposide. The
mice in the control group were injected only with 111In-labeled annexin A5-CCPM.
(B) Tumor uptake of 111In-labeled annexin A5-CCPM, 111In-labeled CCPM, and
99m
Tc-HYNIC-annexin A5 in the EL4 tumor of mice treated with
cyclophosphamide and etoposide. Data obtained using the radioactivity count
method plotted as percentage of injected dose per gram of tissue (%ID/g). All
the data are expressed as mean ± standard deviation. * Indicates statistically
significant change in values with P <0.001.
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Figure 15. Biodistribution 48 h after the administration of 111In-labeled annexin
A5-CCPM in mice bearing EL4 lymphoma. The mice in the chemotherapy group
were injected with 111In-labeled annexin A5-CCPM intravenously 24 h after
administration of cyclophosphamide and etoposide. The mice in the control
group were injected only with 111In-labeled annexin A5-CCPM. (A)
Representative near-infrared fluorescence images of various tissues resected
from mice at the end of the imaging session. (B) Data obtained using the
fluorescence intensity measurement method plotted as photon count per gram of
tissue. All the data are expressed as mean ± standard deviation (n = 7). *
Indicates statistically significant change in values with P <0.001.
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8. 38C13 Lymphoma Apoptosis Mode
Treatment of mice bearing 38C13 lymphoma with cyclophosphamide
induces substantial apoptosis (11). This model was used to further evaluate the
potential of

111

In-labeled annexin A5-CCPM for imaging tumor apoptosis. Figure

16 compares µSPECT and FMT optical images of mice without treatment and
mice treated with cyclophosphamide 48 h after administration of

111

In-labeled

annexin A5-CCPM. The apoptotic tumors were readily visualized in the mice
bearing 38C13 lymphoma after treatment of cyclophosphamide, while the
tumors in the untreated mice were not detected (Figs. 16A and 16B). Both
autoradiographic images (Fig. 16C) and fluorescence optical images (Fig. 16D)
of tumor sections showed Intratumoral distribution of

111

In-labeled annexin A5-

CCPM. Tumor sections from chemotherapy group exhibited higher radioactivity
and fluorescent signal intensity than tumor sections from control group, which
was generally in concordance with whole-body scanning results. Localization of
both radioactivity and fluorescence signal from

111

In-labeled annexin A5-CCPM

correlated with apoptotic cells stained with caspase-3 antibody (Figs. 16C-16F).
Moreover, immunohistochemical analysis confirmed co-localization of
labeled annexin A5-CCPM and apoptotic areas (Fig. 17).

~ 55 ~

111

In-

Figure 16. Dual SPECT/CT and near-infrared fluorescence optical imaging of
38C13 lymphoma apoptosis with 111In-labeled annexin A5-CCPM. The mice in
the control group (top) were injected intravenously only with 111In-labeled
annexin A5-CCPM. The mice in the chemotherapy group (bottom) received an
intravenous injection of 111In-labeled annexin A5-CCPM 24 h after treatment with
cyclophosphamide 100 mg/kg by intraperitoneal injection. (A) Representative
SPECT/CT images. (B) Representative fluorescence molecular tomographic
images. (C) Representative autoradiographs of excised tumors. (D)
Fluorescence images of the same slides used in autoradiographic studies. (E
and F) Immunohistochemical staining with caspase-3 (brown) of the same slides
used in autoradiographic studies. All images were acquired 48 h after injection of
111
In-labeled annexin A5-CCPM.
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Figure 17. Fluorescence microscopy of 38C13 lymphoma from mice treated with
chemotherapy. The tumor sections were subjected to TUNEL staining (green).
Signal from Cy7 loaded annexin A5-CCPM was pseudocolored red and cell
nuclei were counterstained with DAPI (blue). Scale bar: 20 µm.
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The biodistribution data (Fig. 18) were consistent with imaging study (Fig.
16). At 48 h after injection,

111

In-labeled annexin A5-CCPM showed significantly

higher uptake in the tumor of the treated mice (4.84 %ID/g) as compared to the
untreated mice (0.49 %ID/g) (p <0.001) (Fig. 18). The tumor-to-blood ratios
increased from 0.2 in control group to 2.8 in chemotherapy group, and the
tumor-to-muscle ratios increased from 4.6 to 22.7. In the meantime, there was
relatively high uptake of

111

In-labeled annexin A5-CCPM in the livers and

spleens.

Figure 18. Biodistribution in mice bearing 38C13 lymphoma 48 h after the
administration of 111In-labeled annexin A5-CCPM. The mice in the chemotherapy
group were injected with 111In-labeled annexin A5-CCPM intravenously 24 h
after administration of cyclophosphamide (black). The mice in the control group
were injected only with 111In-labeled annexin A5-CCPM (white). Data obtained
using the radioactivity count method plotted as percentage of injected dose per
gram of tissue (%ID/g). All the data are expressed as mean ± standard deviation.
* Indicates statistically significant change in values with P <0.001.
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9. 9L Gliosarcoma Tumor Apoptosis Model
The treatment of cyclophosphamide also can induce 9L gliosarcoma
tumor apoptosis in mice (12). This model was used to further investigate the
potential of

111

In-labeled annexin A5-CCPM for imaging tumor apoptosis. Figure

19 compares µSPECT and FMT optical images of mice without treatment and
mice treated with cyclophosphamide 48 h after administration of

111

In-labeled

annexin A5-CCPM. The apoptotic tumors were clearly visualized in the mice
bearing 9L gliosarcoma tumor after treatment of cyclophosphamide (Figs. 19A
and 19B). In contrast, there was no detectable uptake in the tumors of the
untreated mice (Figs. 19A and 19B). Intratumoral distribution of

111

In-labeled

annexin A5-CCPM was shown in both autoradiographic images (Fig. 19C) and
fluorescence optical images (Fig. 19D) of tumor sections. In comparison with
control group, chemotherapy group exhibited relatively high radioactivity and
fluorescent signal intensity in their tumor sections, which confirmed there was
relatively high uptake in apoptotic tumors. Furthermore,

111

In-labeled annexin

A5-CCPM co-localized with apoptotic areas stained with TUNEL (Fig. 20).
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Figure 19. Dual SPECT/CT and near-infrared fluorescence optical imaging of 9L
gliosarcoma tumor apoptosis with 111In-labeled annexin A5-CCPM. The mice in
the control group (top) were injected intravenously only with 111In-labeled
annexin A5-CCPM. The mice in the chemotherapy group (bottom) received an
intravenous injection of 111In-labeled annexin A5-CCPM 24 h after treatment with
cyclophosphamide 100 mg/kg by intraperitoneal injection. (A) Representative
SPECT/CT images. (B) Representative fluorescence molecular tomographic
images. (C) Representative autoradiographs of excised tumors. (D)
Fluorescence images of the same slides used in autoradiographic studies. All
images were acquired 48 h after injection of 111In-labeled annexin A5-CCPM.
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Figure 20. Fluorescence microscopy of 9L gliosarcoma tumor from mice treated
with chemotherapy. The tumor sections were subjected to TUNEL staining
(green). Signal from Cy7 loaded annexin A5-CCPM was pseudocolored red and
cell nuclei were stained with DAPI (blue). Scale bar: 20 µm.

~ 61 ~

The biodistribution data (Fig. 21) generally confirmed the imaging result
(Fig. 19). At 48 h after injection,

111

In-labeled annexin A5-CCPM exhibited

significantly higher uptake in the tumors of the chemotherapy group (6.41 %ID/g)
than in the tumors of the control group (2.91 %ID/g) (P <0.001) (Fig. 21). The
tumor-to-blood ratios were 1.9 in the control group versus 3.2 in the
chemotherapy group, and the tumor-to-muscle ratios were 7.9 in the control
group versus 18.2 in the chemotherapy group. Similarly, there was significantly
higher uptake of

111

In-labeled annexin A5-CCPM in spleens of the mice treated

with cyclophosphamide than in spleens of the control mice (P <0.001) (Fig. 21).
That is probably because cyclophosphamide induced spleen apoptosis (83).

Figure 21. Biodistribution in mice bearing 9L gliosarcoma tumor 48 h after the
administration of 111In-labeled annexin A5-CCPM. The mice in the chemotherapy
group were injected with 111In-labeled annexin A5-CCPM intravenously 24 h
after administration of cyclophosphamide (black). The mice in the control group
were injected only with 111In-labeled annexin A5-CCPM (white). Data obtained
using the radioactivity count method plotted as percentage of injected dose per
gram of tissue (%ID/g). All the data are expressed as mean ± standard deviation.
* Indicates statistically significant change in values with P <0.001.
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10. MDA-MB-468 Breast Tumor Apoptosis Model
As previously described by Ke Shi (13), MDA-MB-468 breast tumor could
be induced apoptosis by treatment of poly (L-glutamic acid)-paclitaxel and
cetuximab. In order to further evaluate the potential application of

111

In-labeled

annexin A5-CCPM for imaging drug-induced tumor apoptosis, this model was
also applied in this study. Figure 22 compares µSPECT and FMT optical images
of mice without and with chemotherapy 48 h after administration of

111

In-labeled

annexin A5-CCPM. The apoptotic tumors were readily visualized in the mice
bearing MDA-MB-468 breast tumor after chemotherapy, while the tumors in the
untreated mice were not detected (Figs. 22A and 22B). Both autoradiographic
images (Fig. 22C) and fluorescence optical images (Fig. 22D) of tumor sections
showed Intratumoral distribution of

111

In-labeled annexin A5-CCPM. Tumor

sections from chemotherapy group exhibited higher radioactivity and fluorescent
signal intensity than tumor sections from control group, which was generally in
concordance

with

results

of

the

whole-body

scanning.

immunohistochemical analysis confirmed co-localization of

111

A5-CCPM and apoptotic areas stained with TUNEL (Fig. 23).
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Moreover,

In-labeled annexin

Figure 22. Dual SPECT/CT and near-infrared fluorescence optical imaging of
MDA-MB-468 tumor apoptosis with 111In-labeled annexin A5-CCPM. The mice in
the chemotherapy group (bottom) received an intravenous injection of 111Inlabeled annexin A5-CCPM after treatment with poly(L-glutamic)-paclitaxel
conjugate (100 mg eq. paclitaxel/kg by intravenous injection; day 1) and
cetuximab (1 mg/mouse by intraperitoneal injection; day 4). The mice in the
control group (top) were injected intravenously only with 111In-labeled annexin
A5-CCPM. (A) Representative SPECT/CT images. (B) Representative
fluorescence
molecular
tomographic
images.
(C)
Representative
autoradiographs of excised tumors. (D) Fluorescence images of the same slides
used in autoradiographic studies. All images were acquired 48 h after injection of
111
In-labeled annexin A5-CCPM.
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Figure 23. Fluorescence microscopy of MDA-MB-468 breast tumor from mice
treated with chemotherapy. The tumor sections were subjected to TUNEL
staining (red). Signal from Cy7 loaded annexin A5-CCPM was pseudocolored
green and cell nuclei were stained with DAPI (blue).
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11. Hepatic Apoptosis Model
Anti-Fas antibody, which binds to hepatic Fas receptors, can be used to
induce massive apoptosis of hepatocytes in mice within a few hours, mimicking
fulminant hepatitis (14). In histological analysis (Fig. 24E), hepatocytes in the
liver treated with anti-Fas antibody exhibited pyknosis of nuclei and
condensation of the cytoplasm, which are typical features of apoptotic cell death.
It demonstrated that anti-Fas antibody, Jo2, could rapidly induce massive
apoptosis in the liver of mice, mimicking fulminant hepatitis. As shown in Figures
111

24A and 24B,

In-labeled annexin A5-CCPM exhibited significantly high

accumulation in the apoptotic liver treated with anti-Fas antibody. In contrast,
low signals were detected in healthy livers of untreated mice after injection of
111

In-labeled annexin A5-CCPM and in apoptotic livers of treated mice after
111

injection of

In-labeled plain CCPM (Figs.

24A and

24B).

Both

autoradiographic images (Fig. 24C) and fluorescence optical images (Fig. 24D)
of hepatic sections also showed there was relatively high signal intensity in the
apoptotic liver after administration of 111In-labeled annexin A5-CCPM.
The biodistribution data further confirmed the imaging results. The uptake
values of

111

In-labeled annexin A5-CCPM in apoptotic liver (35 %ID/g) was 2

times higher than its uptake value in healthy liver (10 %ID/g) (P <0.001) (Fig.
25). In addition, 111In-labeled annexin A5-CCPM (35 %ID/g) also showed 3 times
higher uptake in apoptotic liver than

111

In-labeled plain CCPM (7.8 %ID/g) (P

<0.001) (Fig. 25).
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Figure 24. Dual SPECT/CT and near-infrared fluorescence optical imaging of
hepatic apoptosis with 111In-labeled annexin A5-CCPM. The mice received
intravenous injection of 111In-labeled annexin A5-CCPM 2 h after treatment with
anti-Fas antibody 10 ug/mouse (left) or PBS (middle) by intravenous injection.
The mice were injected intravenously with 111In-labeled plain CCPM 2 h after
anti-Fas antibody treatment (right). (A) Representative SPECT/CT images. (B)
Representative fluorescence molecular tomographic images. (C) Representative
autoradiographs of excised tumors. (D) Fluorescence images of the same slides
used in autoradiographic studies. (E) H&E staining of the same slides used in
autoradiographic studies. All images were acquired 3 h after injection of 111Inlabeled nanoparticles.
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Figure 25. Biodistribution in hepatic apoptosis model 3 h after the administration
of 111In-labeled annexin A5-CCPM or 111In-labeled CCPM. The mice received
intravenous injection of 111In-labeled annexin A5-CCPM 2 h after treatment with
anti-Fas antibody (black) or PBS (gray) by intravenous injection. The mice were
injected intravenously with 111In-labeled plain CCPM 2 h after anti-Fas antibody
treatment (white). Data obtained using the radioactivity count method plotted as
percentage of injected dose per gram of tissue (%ID/g). All the data are
expressed as mean ± standard deviation. * Indicates statistically significant
change in values with P <0.001.
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12. Inflammation Model
Turpentine can be used as a stimulus to trigger a series of inflammation
reactions by intramuscular injection, such as migration of granulocytes to the
injured tissues, and clearance of apoptotic granulocytes through PS-specific
recognition by monocytes (15). In Figures 26A and 26B, the right thigh abscess
was readily visualized by both nuclear and optical imaging after intravenous
administration of

111

In-labeled annexin A5-CCPM, whereas the left control thigh

was not detected.

Figure 26. Dual SPECT/CT and near-infrared fluorescence optical imaging of
inflammation with 111In-labeled annexin A5-CCPM. The mice received
intravenous injection of 111In-labeled annexin A5-CCPM 24 h after treatment with
turpentine or PBS 100 uL/mouse by intramuscular injection. (A) Representative
SPECT/CT images. (B) Representative fluorescence molecular tomographic
images. All images were acquired 48 h after injection of 111In-labeled annexin
A5-CCPM.
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Autoradiographic, fluorescence optical and histological images of muscle
sections confirmed the intensely focal zones of

111

In-labeled annexin A5-CCPM

co-localized to the inflammatory areas with infiltration of granulocytes and less
monocytes adjacent to abscess cavities (Figs. 27A-27C).

Figure 27. Autoradiography, optical imaging and immunohistochemical analysisi
of muscle section with 111In-labeled annexin A5-CCPM. The mice received
intravenous injection of 111In-labeled annexin A5-CCPM 24 h after treatment with
turpentine or PBS 100 uL/mouse by intramuscular injection. (A) Representative
autoradiographs of excised tumors. (B) Fluorescence images of the same slides
used in autoradiographic studies. (C) H&E staining of the same slides used in
autoradiographic studies. All images were acquired 48 h after injection of 111Inlabeled annexin A5-CCPM.
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Biodistribution data showed a general concordance with the imaging
results, with the uptake value of 4.9 (%ID/g) in the thigh abscess after injection
of

111

In-labeled annexin A5-CCPM, as compared to the values of 0.6 (%ID/g) in

the healthy thigh after injection of

111

In-labeled annexin A5-CCPM and 2.3

(%ID/g) in the thigh abscess after injection of 111In-labeled plain CCPM (p<0.001)
(Fig. 28). Interestingly,

111

In-labeled CCPM also exhibited higher uptake in the

thigh abscess (2.3 %ID/g) than in the health thigh (0.4 %ID/g) (p<0.001) (Fig.
28).

Figure 28. Thigh uptake of 111In-labeled annexin A5-CCPM and 111In-labeled
CCPM in mice treated with turpentine or PBS. Data obtained using the
radioactivity count method plotted as percentage of injected dose per gram of
tissue (%ID/g). All the data are expressed as mean ± standard deviation. *
Indicates statistically significant change in values with P <0.001.
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DISCUSSION

In this study, we found that injection of

111

In-labeled annexin A5-CCPM

allowed ready visualization of drug-induced apoptosis with both SPECT and
near-infrared fluorescence imaging in 6 different apoptosis models. Moreover,
111

In-labeled annexin A5-CCPM permitted detection of apoptotic cells at the

microscopic level by optical imaging.
Apoptosis is a dynamic process in which newly generated apoptotic cells
are rapidly removed by phagocytic macrophages (146). Therefore, there is a
short "time window" during which apoptotic cells display their characteristic
features such as externalization of Phosphatidylserine to the outer leaflet of cell
membrane. Generally, the time from initiation of apoptosis to completion occurs
as quickly as 2 - 3 h. Furthermore, the peak apoptotic activity after therapy
varies from treatment to treatment and from patient to patient. Thus, it is critical
that apoptosis is captured at its peak or over a prolonged period during which
apoptotic responses exists to maximize the detection sensitivity when using PSbinding ligands. Currently,

99m

Tc-labeled annexin A5 is widely used in detection

of apoptosis. Owing to its short blood half-life (<7 min) (13), it has been
suggested that an imaging protocol using multiple separate injections of

99m

Tc-

labeled annexin A5 and multiple radionuclide scans could be used to assess
peak apoptotic activity. Such a protocol, however, may be difficult to implement
in larger-scale trials, because there probably is blocking interference between
repetitive doses of annexin A5. It has been reported that annexin A5 can
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strongly bind to 3 PS molecules on the cell surface with a nanomolar affinity
(147). Thus, it is possible that the previous injection of annexin A5 may still tie
up PS on the cell surface and thereby compromise the ability of the later dose to
bind. We hypothesized that modulation of the pharmacokinetics of annexin A5
through the use of long-circulating nanoparticles would permit single injection of
this tracer to monitor apoptotic process over a prolonged period of time, avoiding
an imaging protocol with multiple injections. On the other hand, due to short
circulation time in vivo,

99m

Tc-labeled annexin A5 exhibits limited exposure time

and penetration into tumor mass, which compromise its sensitivity. Therefore,
the

introduction

of

long-circulating

nanoparticles

permits

annexin

A5-

nanoparticles to penetrate deep and increase its uptake in apoptotic tissues. In
this study, annexin A5 was conjugated to the surface of polyethylene glycolcoated CCPM. Although introduction of annexin A5 molecules to CCPM resulted
in significant reduction in the blood half-life of the resulting annexin A5-CCPM as
compared to the unmodified CCPM (Table 6), the mean half-life of 12.5 h was
still much longer than that of annexin A5. We found that while conventional
99m

Tc-HYNIC annexin A5 showed an uptake value of 4.14 %ID/g in EL4

lymphoma of the treated mice,

111

In-labeled annexin A5-CCPM showed an

uptake value of 8.01 %ID/g, indicating that prolonging the blood half of annexin
A5 could lead to increased uptake of the radiotracer in apoptotic tumors. The
increased tumor uptake of

111

In-labeled annexin A5-CCPM was not a result of

increased permeability and retention effect, because

111

In-labeled CCPM, which

had longer blood half life than annexin A5-CCPM, displayed only 2.81 %ID/g in
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the treated tumors (Fig. 14B). Taken together, our data support the notion that
increasing the half-life of annexin A5 improved the level of uptake signal in
apoptotic tissues and was superior for noninvasive detection of apoptotic cells.
The introduction of CCPM nanoparticles to annexin A5 also may improve
uptake of annexin A5 in apoptotic tissues through multivalent effect. The overall
strength of nanoparticle binding to target cells depends on both the affinity of the
ligand-target interaction and the number of targeting ligands present on the
nanoparticle surface. Nanoparticles containing multiple targeting ligands can
provide multivalent binding to cell surface receptors (148). Multivalent effect has
advantages over monovalency for binding interactions and can increase the
avidity of interaction of ligands to their target receptor. Using multivalent
targeting systems, including dimers, tetramers, and multimers, has been
reported as a successful strategy for enhancing the avidity and/or biological
functions of peptides, proteins, and antibodies (149-153). This approach is
particularly useful for ligands that have a weak affinity to their target receptors in
their monomer form. For example, trastuzumab, an engineered antibody for
Her2+ breast cancer therapy, was increased in potency up to 25 times through
conjugation to liposomes (154). In our study, each annexin A5-CCPM
nanoparticle contained approximately 40 annexin A5 molecules on the surface.
Thus, the repertoire of annexin A5 was greatly expanded due to multiple,
simultaneous interactions between the surface of the nanoparticle and the
surface of the apoptotic cell. The in vitro studies of binding to apoptotic cells
showed that

111

In-labeled annexin A5-CCPM displayed higher detection
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sensitivity with radioactivity binding assay than monomeric FITC-annexin A5 with
flow cytometry assay, possibly as a result of increased binding avidity (Fig. 11).
Similarly, CCPM nanoparticles conjugated with multiple peptides also showed
multivalent effect in our previously published study (155). The surface plasmon
resonance (SPR) sensorgrams of this peptide-conjugated CCPM failed to fit into
the standard 1:1 or 1:2 binding models, indicating that the binding kinetics
between receptor and peptide-conjugated CCPM were complex. The complex
binding profile probably was induced by the multivalent nature of this
nanoparticle. (Reprinted with the permission of (155))
In addition to prolonged circulation time and multivalent effect, the
enhanced permeability and retention (EPR) effect of CCPM nanoparticles also
benefit uptake of this imaging tracer in apoptotic areas, which is a form of
selective targeted delivery termed as passive targeting. The blood vessels in
some disease areas (such as tumors, inflammations, and infarcted areas) are
irregular in shape, dilated, leaky or defective, and the endothelial cells are poorly
aligned. Also, the perivascular cells and the basement membrane are frequently
absent in the vascular wall. Therefore, long-circulation colloidal particles can
slowly accumulate in pathological sites with affected and leaky vasculature,
which is termed as EPR effect (156-160). It strongly depends on the cutoff size
of blood vessel wall in disease areas (161, 162). Because the usual size of a
polymeric micelle is 10-80 nm, this passive manner of delivery without specific
binding to cellular targets has been demonstrated highly effective for polymeric
micelles (158). It has been repeatedly shown that polymeric micellar
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nanocarriers, such as adriamycin better accumulate in targeted disease areas
than in non-target tissues, thus minimizing the undesired drug toxicity towards
normal tissue (158, 163). Recently, a number of micellar drugs are in
development based on this mechanism and the EPR effect is becoming a
golden standard of drug design. Importantly, the EPR effect is a molecular
weight-dependent phenomenon and functions for molecules or particles larger
than 60 kDa, which is the threshold of renal clearance. It does not apply to lowmolecular-weight drugs like annexin A5 (160). Therefore, annexin A5 was
conjugated to CCPM in this study, which also acted as a secondary uptake
mechanism following EPR-based primary accumulation for better targeting.
Annexin A5 derivatives labeled with fluorescent dyes for optical imaging
or radioisotopes for nuclear imaging have been reported for detection of
apoptosis in preclinical and clinical studies, respectively (14, 15, 22, 23, 78, 8084, 86, 102, 164). However, it is highly desirable that an imaging probe
combining a radioisotope and a near-infrared fluorescent dye be available for
dual nuclear and optical imaging (165). Nuclear imaging (e.g. PET/CT,
SPECT/CT), an established clinical imaging modality, offers excellent sensitivity
and covers the whole body. However, nuclear imaging techniques are limited by
high cost, radiation exposure and relatively poor spatial resolution. Optical
imaging techniques have the potential to offer real-time, high-resolution images
of tissues as long as they are accessible with near-infrared light. Such real-time
imaging techniques particularly play an important role when studying organs in
motion, like the beating heart. Moreover, real-time imaging of spontaneous or

~ 76 ~

therapy-induced apoptosis could facilitate and speed up clinical decision.
Furthermore, the fluorescent signal from the imaging probes permits ex vivo
analysis of excised tissues and validation of its binding to the molecular targets
in vivo. Since no imaging modality is perfect, the combination of 2 or more
imaging techniques can therefore offer synergistic advantages over 1 modality
alone in providing valuable diagnostic information. To date, several nanoparticlebased multimodal imaging probes have been developed and applied for
multimodality functional imaging in living animals (166, 167). These multimodal
imaging systems have shown great promise in preclinical drug development and
biomedical research. In this study, Cy-7 dye was entrapped in the core of CCPM
and radioisotope chelator DTPA was conjugated on the surface of CCPM. Each
micellar nanoparticle was loaded with multiple Cy7 dye molecules and 111In ions,
providing a huge boost in signal intensity. As shown in both nuclear and optical
imaging,

111

In-labeled annexin A5-CCPM potentially can be used to locate

apoptosis by whole-body nuclear and optical imaging. Histologically,

111

In-

labeled annexin A5-CCPM revealed apoptotic areas in whole-body scanning
consistent with autoradiographic and fluorescent findings of tumor sections.
(Reprinted with the permission of (155))
Apoptosis occurs during the normal development and continues
throughout the whole life. Abnormal apoptosis, especially too much apoptosis,
can lead to disorders of normal tissues, such as myocardial diseases,
neurodegenerative

diseases,

autoimmune

diseases,

and

rejection

of

transplanted organs (liver, heart, lung, kidney) (1, 20-28). Therefore, imaging
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apoptosis has broader applications other than the monitoring of drug-induced
tumor apoptosis (168). It is necessary to demonstrate that apoptosis in all types
of tissues can be visualized by our imaging tracer. In this study, our data showed
that

111

In-labeled annexin A5-CCPM had a great potential for imaging apoptosis

not only in 4 different tumor apoptosis models, also in hepatic apoptosis and
inflammation models. In 2 tumor apoptosis models, We observed that

111

In-

labeled annexin A5-CCPM preferentially localized at the regions of splenic and
intramedullary

apoptotic

injury

induced

by

intraperitoneal

injection

of

cyclophosphamide (Figs. 14A and 21) - a finding that is consistent with the
previous reports (83, 144). In addition, recent studies suggest that localization of
annexin A5 does not appear to be entirely specific for apoptosis. Expression of
PS also occurs with nonlethal cell injury prior to the irreversible changes such as
DNA breakdown (169, 170). Early identifying expression of PS in injured cells
may be helpful to defining tissues at risk of cell death and applying therapeutic
recovery. Annexin A5 is also able to binds to necrotic cells, because of exposure
of PS located in the inner leaflet of the highly permeable cell membrane of
necrotic cells (99).
Since inflammation is associated with a host of diseases, detection of
inflammation is critical to diagnosis and treatment (171-176). The possibility of
diagnosing inflammatory processes in the early stage may allow for prevention
of diseases and early therapeutic intervention. Several Imaging techniques have
been developed for diagnosis of inflammation, such as ultrasound, CT, MRI,
PET, and SPECT. Nuclear medicine imaging procedures play an important role
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in the assessment of inflammatory diseases. Currently, only a few agents are
18

used for imaging inflammation in clinic, such as
bisphosphonates,

99m

Tc or

F-FDG,

99m

Tc-labeled

111

In-labeled white blood cells, and radio-labeled

protein (IgG, albumin). The accumulation of these agents in the site of
inflammation is generally based on two different mechanisms (177). One is
specific uptake by inflammatory tissue as a result of increased activities or
specific cells associated with inflammation, such as

18

F-FDG and

99m

Tc-labeled

bisphosphonates. The other is unspecific accumulation in inflammatory sites
because of enhanced vascular permeability. We hypothesize that the
combination of these two mechanisms might make imaging more sensitive and
specific. It has been reported that radio-labeled annexin A5 can be used to
identify macrophages in the site of inflammation in vivo. In our study, CCPM
nanoparticles displayed higher uptake in inflammatory muscle than in healthy
muscle (Fig. 28), probably because of enhanced permeability of blood vessels.
Our design takes advantages of these two mechanisms to increase the uptake
of this nano-tracer in the site of inflammation and thus improve sensitivity of
diagnosis.
In ex vivo studies, apoptotic cells in tissue sections are generally detected
using transmission electron microscopy (TEM) or microscopy incorporated with
immunostaining such as H&E and TUNEL (9). Among these assays, TEM is
considered a golden standard to confirm apoptosis, because of irrefutable
categorization

of

an

apoptotic

cell

containing

certain

ultrastructural

morphological characteristics (9, 34). However, because the morphological
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changes generally occur in the later phase of apoptosis, apoptotic cells in the
early phase will not be detected with these methods. Additionally, TEM is high
cost, time expenditure, and only allows visualization of a small region at a time.
Similarly, H&E assay is also based on the morphological changes of apoptotic
cells. However, these changes rapidly occur in the later phase of apoptosis and
the fragments are quickly phagocytized so that considerable apoptosis may
occur in some tissues before it is histologically apparent and cells are in early
phase of apoptosis will not be detected (9). Due to the ability to detect DNA
degradation that occurs in a later phase of apoptosis, TUNEL is not suitable for
cells in the early phase of apoptosis, neither (9, 35). Taken together, regarding
the mechanisms of these three assays mentioned above, their main
disadvantage is limitation to the early phase of apoptosis. Therefore, it is very
desirable to develop a non-invasive imaging tracer that can early and accurately
detect occurance of apoptosis. This imaging tracer needs to be specifically
designed on events that occur in the early phase of apoptosis. Externalized PS
on the outer plasma membrane of apoptotic cells in the early phase of apoptosis
is considered an optimal marker, which allows for early detection apoptosis via
annexin A5 (41-44). This assay is sensitive (can detect a single apoptotic cell),
fast, inexpensive and easy-to-use (9). Thus, we developed annexin A5functionalized tracer for imaging apoptosis in this study. Immunohistochemical
analysis demonstrated a high correlation between localization of

111

In-labeled

annexin A5-CCPM with sites of apoptosis as confirmed by staining with TUNEL,
H&E and anti-caspase 3 antibody. To sum up,
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111

In-labeled annexin A5-CCPM

has a great potential to early capture occurrence of apoptosis instead of
conventional histological methods, which is critical and can result in improved
patient outcomes.
Though this

111

In-labeled annexin A5-CCPM showed a great potential in

the application of imaging apoptosis in mice, there is still a long way to go if we
translate it into clinic. It is necessary to perform further studies to investigate it,
including toxicity, stability, clearance, and efficacy. First, toxicity is considered
one of the most important properties in the development of new medicines.
There are thousands of medicines that can’t get the approval from FDA because
of high toxicity. Therefore, a series of toxicity studies are supposed to be
conducted in the near future. Secondly, there are many evidences that corecross-linked polymeric micelles are relatively stable, especially when they are
coated with PEG shells. Both autoradiography and optical imaging of tumor
sections demonstrated that radioactivity signal co-localized with fluorescence
signal, indicating that CCPM was stable at 48 h post-injection in vivo. However,
the long-term stability still needs to be elucidated. In addition to toxicity and
stability, clearance also needs to be considered. It is well known that size of
nanomedicines generally ranges from 10nm to 1000nm, which is over the
threshold of renal clearance. Most of nanomedicines are hardly excreted through
kidney, resulting in accumulation in the bodies for a long period. Therefore, it is
highly desired to develop degradable nanomedicines for future clinical
application. In the past few years, a variety of degradable nanomedicines have
been reported and showed a great potential in drug delivery. Our group is also
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working on that area. Now we have synthesized the second generation of CCPM
and made it easily degradable in human body. Our studies demonstrated that
the second generation of CCPM still kept advantages of first generation. In the
future, we will conjugate targeting ligands like annexin A5 to new CCPM for
imaging apoptosis.
To the end, we envision the following clinical scenario: A patient with a
suspected abnormal apoptosis lesion will be intravenously administered with a
single dose of our imaging tracer dual-labeled with radionuclide and optical
fluorophore. Initially the localization of abnormal apoptotic areas will be
visualized by whole-body nuclear scanning (SPECT/CT). Subsequently, the
optical imaging guidance will be applied during surgery procedure to accurately
remove the abnormal mass. In the meantime, the optical imaging guided
biopsies could be performed which will be aided by real-time fiber optical
confocal microscopy imaging “from the tip of the needle” to minimize the falsenegative biopsies.
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CONCLUSIONS

In this study, we evaluated the potential application of

111

In-labeled

annexin A5-conjugated polymeric micelles for multimodal detection of druginduced apoptosis. In 6 different apoptosis models, apoptosis was readily
visualized with

111

In-labeled annexin A5-CCPM using both SPECT and near-

infrared fluorescence imaging. Moreover, annexin A5-CCPM permitted early
detection of apoptotic cells at the microscopic level by optical imaging for a more
complimentary diagnosis.
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